Amlodipine: Increased systemic exposure in elderly hypertensive patients (69-87 yr) w/ diltiazem. Increased plasma conc w/ strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir). Increased risk of hypotension w/ clarithromycin. Lower plasma conc w/ CYP3A4 inducers (eg, rifampicin, Hypericum perforatum
). Increased bioavailability w/ grapefruit juice. Affects trough conc of cyclosporine. Increased tacrolimus blood levels. Increased exposure of mechanistic target of rapamycin inhibitors (eg, sirolimus, temsirolimus, everolimus). Atorvastatin: Increased risk of myopathy w/ cyclosporine, fibric acid derivatives, niacin, erythromycin, azole antifungals. Increased plasma conc w/ CYP3A4 inhibitors, erythromycin or clarithromycin, PIs, diltiazem, excessive grapefruit juice consumption (>1.2 L/day). Increased bioavailability w/ OATP1B1 inhibitors (eg, cyclosporine). Increased AUC w/ itraconazole. Decreased plasma conc w/ CYP3A4 inducers (eg, efavirenz, rifampin), antacids containing Mg & Al hydroxide; colestipol. Increased digoxin conc. Increased AUC values for OCs (eg, norethindrone, ethinyl estradiol). Increased risk of rhabdomyolysis w/ fusidic acid. Cases of myopathy w/ colchicine.